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Abstract. Near-infrared spectroscopy (NIRS) measurements of cytochrome-c-oxidase (CCO) have the potential
to yield crucial information about cerebral metabolism at the patient bedside. Developments in instrumentation
and the analytical methods used to resolve changes in CCO have led to many clinical applications of the meas-
urement since its first demonstration in 1977 by Jöbsis. There is a substantial literature of work on measures of
CCO in animal and in vitro studies; however, this review focuses on translational studies. Almost 40 years from
the advent of the first measurement of CCO using NIRS, this signal continues to hold significant interest in our
understanding of the human brain in health and disease. We discuss methodologies for obtaining NIRS mea-
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1 Introduction
A patient’s health is in great danger when there is a prolonged
lack of oxygen delivery to meet the metabolic demand of the
tissue; even brief periods of hypoxia can cause permanent dam-
age to brain tissue. This is a huge problem in patients with acute
brain injury, for example, where derangements of cerebral oxy-
gen delivery and utilization often occur, rendering the brain sus-
ceptible to secondary, or additional, injury processes. Secondary
injury is also common in neonatal brain injury after perinatal
hypoxia-ischemia (HI), affecting neurodevelopmental outcome.
A number of hemoglobin-based oxygenation monitors are avail-
able; however, clinicians currently cannot monitor the biochemi-
cal status of the injured brain continuously and noninvasively at
the bedside. There is therefore an urgent need for real-time, in
vivo measurements of brain tissue oxygenation and biochemis-
try in the clinic; a need for a bedside sensor that can improve
diagnostic information and indicate when to alter and/or redirect
therapy to improve clinical outcome.
Since 1977, when Franz Jöbsis reported a new optical method
in a seminal Science article,1 near-infrared spectroscopy (NIRS)
has been seen as the technique, which could deliver a solution to
this clinical need. NIRS has become an established research and
clinical tool for measuring changes in cerebral oxygenation, in
particular, changes in oxygenated and deoxygenated hemoglobin
(HbO2 and HHb) concentration. This groundbreaking paper has
been cited close to 3000 times. However, Jöbsis’s intention was to
develop an optical technique to measure in vivo changes in cyto-
chrome-c-oxidase (CCO), an enzyme in the mitochondria, and
hence monitor tissue metabolism (see his candid account of
his discovery2). Jöbsis discovered that near-infrared (NIR) light
penetrates deep into living tissue and this optical window could
be used to monitor changes in the concentrations of absorbing
compounds inside the tissue. The tissue light attenuation mea-
surements are related to changes in the concentrations of HbO2
and HHb, and the redox state of CCO. The legacy of Jöbsis’s
work lies in the measurement of changes in hemoglobin oxygena-
tion with NIRS, as it is much simpler to measure the hemoglobin
chromophores, which are present in high concentrations com-
pared to CCO; but his goal of an in vivo monitor of tissue metabo-
lism is as important today as it was almost four decades ago.
There has been a significant amount of work on measuring
hemoglobin concentration changes with NIRS since 1977 (see
the recent reviews by Wolf et al.3 and Scholkmann et al.4). A
typical commercially available NIRS system is a noninvasive, in-
expensive, portable, bedside monitor that can measure, at multiple
sites, the changes in HbO2 and HHb via the modified Beer–
Lambert law (described in Ref. 4). From those, it is possible
to derive estimations of changes in oxygen delivery (via hemo-
globin difference, HbD ¼ HbO2 − HHb) and changes in total
blood volume (total hemoglobin,HbT ¼ HbO2 þ HHb). In addi-
tion, from technical developments in the late 1990s, we now have
clinical NIRS cerebral oximeters that measure absolute tissue sat-
uration [known as cerebral oxygen saturation (ScO2), tissue oxy-
gen saturation (StO2), or tissue oxygenation index (TOI)], which
is the ratio of absolute HbO2 and absolute HbT, using techniques,
such as spatially resolved spectroscopy.5,6 However, these mea-
surements do not monitor metabolism at a cellular level unlike
a measurement of the redox state of CCO, which has the potential
to yield an in vivo indication of cellular energy metabolism.
Simultaneous measurement of the CCO and hemoglobin signals
can therefore provide complimentary information on hemo-
dynamics, oxygenation, and metabolism. Monitoring of CCO
with NIRS has been shown to be consistent with other measures
of metabolism; including those from more invasive techniques,
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such as microdialysis in humans,7 or more expensive and less
portable techniques, such as magnetic resonance spectroscopy
(MRS) in animal studies.8–11 Furthermore, the concentration of
CCO is much higher in the brain than in extracerebral tissues,
so it is a more brain-specific signal that is less prone to scalp
and skull contamination than the hemoglobin signals.12,13 This
has potentially huge importance for functional NIRS (fNIRS)
studies in which the hemoglobin signals suffer from contamina-
tion from the extracerebral tissues.14
Preclinical and in vitro studies have contributed enormously
to our understanding of the optical issues surrounding the NIRS
measurement of CCO, its role as marker of cellular metabolism,
and its potential as a clinically relevant measure. This was a
focus for several research groups in the 1980s and 1990s.15–21
More recently, a study in a piglet model of HI brain injury has
demonstrated the specificity of the CCO signal as a marker of
tissue metabolism.10 In this study, the percentage recovery of
CCO after HI to baseline levels was highly correlated with per-
centage recovery of phosphorus (31P) MRS measures of cellular
metabolism (see Fig. 1). Furthermore, this study demonstrates
the potential for CCO measures to identify outcome after injury.
However, in this review, we focus on the translational clinical
and human cerebral studies that have been ongoing since
198522 and we aim to identify and summarize this work from
then until the present day.
Figure 2 shows how the number of publications on and the
populations studied by NIRS-measured CCO has varied over the
years. Between 1977 and 1997, there was a gradual increase in
the number of papers published, varying in subject and research
group [Duke University, University College London (UCL),
Hokkaido University, Sapporo, and Keele University were
home to the main groups involved]. After 1997, the interest
in the CCO measurement gradually declined due to both con-
troversies over the optical instrumentation, methods and algo-
rithms used to resolve it,23 and a shift of clinical interest due
to the emergence of the absolute tissue saturation measurement
with NIRS.5 In the 2000s, efforts were made to optimize NIRS
instrumentation and methods specifically for the measurement
of CCO24,25 and studies were performed in healthy volunteers
and patients to characterize the behavior of the CCO signal
as a marker of cerebral cellular oxygen metabolism.7,13 A resur-
gence in the number of papers published over the last few years
reflects the continued clinical desire for in vivo measures of
metabolism and a renewed interest in the CCO signal following
the demonstration of new technological and analytical methods.
Our focus in this review article is on measurements in
patients and healthy volunteers, however, in order to fully under-
stand the chronology and advances made in the methodology,
some important preclinical work is also discussed. While
there is extensive work on the measurement of CCO changes
in the visual part of the light spectrum (see the review by
LaManna for a historical perspective26), here, we have focused
on the measurements with NIR light (650 to 1000 nm). We aim
to summarize work on the instrumentation, algorithms, and
clinical applications of the CCO signal and assess the current
state of the measurement to look forward to the future of the
technique. We provide a simplified description of the biochem-
istry of the enzyme to understand the origins of the optical sig-
nal; the methods, algorithms, and instrumentation used to study
it; a discussion of the issues with the methodology; a summary
of the applications of cerebral NIRS measurements of CCO in
neonatal and adult studies; and a forward perspective on the
future of the technique. Almost 40 years from the advent of
the first measurement of CCO using NIRS, this signal continues
to hold significant interest and hope in providing the ultimate
noninvasive, in vivo, bedside, and real-time sensor of brain tis-
sue well-being; a sensor with the capacity to indicate when to
alter and/or redirect therapy to improve long-term clinical
outcome.
We are interested in an indicator of the redox state change of
CCO. Previous NIRS studies, both preclinical and clinical, have
referred to this signal as CytOx, aa3, CuA, CCO, and oxCCO.
For clarity, in this review, the term oxCCO is used to describe
the NIRS measurement of the oxidation state of cytochrome-c-
oxidase, which arises from its redox state-dependent changes in
the NIR spectrum. Although the dominant chromophore in the
NIR is the CuA center, other cytochrome redox centers and oxy-
gen intermediates can contribute to this signal.
2 Biochemistry and Spectral Features of
Cytochrome-C-Oxidase
In order to fully understand the CCO NIRS signal, one must
understand the biochemistry from which the signal stems.
CCO is a small but important part of the aerobic metabolism
of glucose. Glycolysis converts glucose into pyruvate and in
the process generates ATP and NADH. After glycolysis, pyr-
uvate is transported into the mitochondria and converted to ace-
tyl CoA, which then enters the tricarboxylic acid (TCA) cycle.
During the TCA cycle, additional ATP and NADH are pro-
duced. NADH is an electron donor; electrons from NADH
can be used to, ultimately, convert oxygen to water, releasing
useful chemical-free energy in the process. The mitochondrial
electron transfer chain (ETC) mediates this transfer, in the proc-
ess converting ADP to ATP. The consequent change in ATP/
ADP ratio provides usable energy to drive a wide variety of
cellular processes.
Fig. 1 Measured changes in oxCCO (see Sec. 2 for a full explanation
of this term) following hypoxia-ischemia (HI) in a piglet model.
Each data point represents the recovery fraction of the broadband
NIRS oxCCO signal and the 31P MRS NTP/epp (a surrogate marker
of ATP). The broadband oxCCO measurements show a strong asso-
ciation (Pearson correlation, r ¼ 0.82) with the 31P MRS metabolic
measurements and provide a good indication of outcome (good out-
come refers to piglets that survived for more than 24 h following HI).
The figure has been produced from data presented by Bainbridge
et al.10
Journal of Biomedical Optics 091307-2 September 2016 • Vol. 21(9)
Bale, Elwell, and Tachtsidis: From Jöbsis to the present day: a review of clinical near-infrared spectroscopy. . .
Downloaded From: http://biomedicaloptics.spiedigitallibrary.org/ on 05/23/2016 Terms of Use: http://spiedigitallibrary.org/ss/TermsOfUse.aspx
Figure 3 shows the mitochondrial protein complexes
involved in this oxidative phosphorylation. Oxidative phospho-
rylation is the process where energy is harnessed through a
series of protein complexes (known as complexes I to V)
embedded in the inner membrane of mitochondria to create
ATP. Oxidative phosphorylation can be broken down into
two parts: oxidation of NADH (and other electron donors) in
the ETC via complexes I to IVand phosphorylation, the produc-
tion of ATP, at Complex V. Complex I accepts electrons from
NADH and transfers them to the soluble membrane-bound elec-
tron carrier ubiquinol (Q), producing ubiquinone (QH2). QH2 is
oxidized by complex III, in the process reducing the soluble
electron transport protein, cytochrome c. Cytochrome c is
then oxidized by the terminal electron acceptor cytochrome-
c-oxidase (also known as complex IV), with the electrons ulti-
mately being used to reduce oxygen to water. The redox poten-
tial drop in the electron transfer processes in complex I, III, and
IV is converted to a proton electrochemical potential, which ulti-
mately drives mitochondrial ATP synthesis via the mitochon-
drial ATP synthase (complex V).
The transfer of electrons within the mitochondrial ETC com-
plexes occurs via a number of protein bound redox factors. Of
particular interest in this review, CCO contains four redox cen-
ters: two hems (known collectively as aa3) and two copper sites
(see Fig. 3). The electrons pass between these centers in a series
of redox reactions. All of these redox changes have associated
optical transitions. In the NIR region, one of the copper sites, the
Cu-Cu dimer copper A (CuA), dominates the absorption spec-
trum, with a strong peak in the oxidized form centered, in mam-
malian enzymes, around 830 to 840 nm (see Fig. 4). For a recent
detailed discussion of the relative contributions of CCO chromo-
phores to the NIR spectrum, see Ref. 30 and references therein.
The difference between these absorption spectra (oxidized-
reduced CCO) can be used to monitor changes in the redox
states of the mitochondrial proteins. Note that the total CCO
concentration does not change over a short-time period (in
the order of hours); therefore, for analytical purposes, it is
only necessary to use the difference spectrum between the oxi-
dized and reduced species to obtain an indicator of the changes
in the CCO redox state.
The UCL group has shown that using the oxidized-reduced
difference spectrum resolves changes in oxidized CCO (and
conversely, using the reduced-oxidized difference spectrum
resolves changes in reduced CCO). The proof uses the modified
Beer–Lambert law and involves two scenarios. In scenario 1
[Eqs. (1)–(5)], CCO is fully oxidized (ox) at the initial time
(t0) and so the Beer–Lambert law states that the attenuation
(A) due to CCO is related only to the concentration (c) of
oxidized CCO, its extinction coefficient (ε), and the optical path-
length of light (l):
EQ-TARGET;temp:intralink-;e001;326;261 ðt0Þ ¼ lεoxCCOCoxCCOðt0Þ: (1)
At a later time (t1), CCO is not fully oxidized and so the attenu-
ation is related to both oxidized and reduced (red) forms of the
enzyme:
EQ-TARGET;temp:intralink-;e002;326;197 ðt1Þ ¼ l½εoxCCOCoxCCOðt1Þ þ εredCCOCredCCOðt1Þ: (2)
Assuming that the total CCO concentration does not change, the
initial concentration of fully oxidized CCO is equal to the sum of
the oxidized and reduced forms at the later time:
EQ-TARGET;temp:intralink-;e003;326;133CoxCCOðt0Þ ¼ CoxCCOðt1Þ þ CredCCOðt1Þ: (3)
Therefore, it is possible to substitute the equations above into
the difference measurement of the attenuation:
Fig. 2 Number of papers published per year on the subject of cerebral NIRSmeasurements of CCO. The
data were taken from the PubMed results for “cytochrome oxidase infrared spectroscopy brain” (with
the addition of the 1977 Jöbsis paper). There are a total of 223 papers split into categories based on
the subject: adults—67 papers (green), neonates—36 papers (red), animals—98 papers (blue) and
other—23 papers (purple, including reviews of the subject, in vitro work and computational simulations).
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EQ-TARGET;temp:intralink-;e004;63;300
ΔA ¼ Aðt1Þ − Aðt0Þ
¼ lfεoxCCO½CoxCCOðt1Þ − CoxCCOðt0Þ
þ εredCCOCredCCOðt1Þg
¼ lfεoxCCO½CoxCCOðt1Þ − CoxCCOðt0Þ
þ εredCCO½CoxCCOðt1Þ − CoxCCOðt0Þg
¼ lðεoxCCO − εredCCOÞΔCoxCCO: (4)
The oxidized-reduced difference (diff) extinction spectrum,
εdiff ¼ εoxCCO − εredCCO, gives rise to Eq. (5), which expresses
the change in attenuation due to a change in the concentration of
oxidized CCO from the difference extinction spectra:
EQ-TARGET;temp:intralink-;e005;63;147ΔA ¼ lεdiffCCOΔCoxCCO: (5)
In a scenario 2 [Eqs. (6)–(10)], where CCO is not fully oxidized
initially (i.e., CCO exists in both oxidized and reduced forms),
the same expression can be achieved:
EQ-TARGET;temp:intralink-;e006;63;83 ðt0Þ ¼ l½εoxCCOCoxCCOðt0Þ þ εredCCOCredCCOðt0Þ; (6)
EQ-TARGET;temp:intralink-;e007;326;289 ðt1Þ ¼ l½εoxCCOCoxCCOðt1Þ þ εredCCOCredCCOðt1Þ: (7)
Assuming again that the total CCO concentration does not
change:
EQ-TARGET;temp:intralink-;e008;326;251CoxCCOðt0Þ þ CredCCOðt0Þ ¼ CoxCCOðt1Þ þ CredCCOðt1Þ:
(8)
Therefore,
EQ-TARGET;temp:intralink-;e009;326;216
ΔA ¼ Aðt1Þ − Aðt0Þ
¼ l½εoxCCOðCoxCCOðt1Þ − CoxCCOðt0ÞÞ
þ εredCCOðCredCCOðt1Þ − CredCCOðt0ÞÞ
¼ l½εoxCCOðCoxCCOðt1Þ − CoxCCOðt0ÞÞ
þ εredCCOðCoxCCOðt1Þ − CoxCCOðt0ÞÞ
¼ lðεoxCCO − εredCCOÞΔCoxCCO; (9)
which gives rise to the same expression as Eq. (5):
EQ-TARGET;temp:intralink-;e010;326;87ΔA ¼ lεdiffCCOΔCoxCCO: (10)
Fig. 3 Schematic of cellular metabolism with the electron transport chain and CCO expanded. CCO is
represented as complex IV. This diagram is limited to the carbohydrate metabolism (from glucose); fat
metabolism, also aerobic, is ignored. Chromophores that are measured by NIRS are highlighted in yellow
boxes.
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These proofs show that the oxidized-reduced difference spec-
trum can be used to resolve changes in the concentration of oxi-
dized CCO. An increase in the oxCCO signal therefore reports
an increase in oxidized CCO and an equivalent decrease in
reduced CCO. Note that if the sign of the measured signal is
changed, it represents reduced CCO, not oxidized CCO. The
oxCCO term does not imply that we are only sensitive to the
oxidized species. Nevertheless, oxCCO is the term used to
describe the measured changes from the difference spectra in
this review article.
To understand what a change in oxCCO means physiologi-
cally we need to know what the concentration of oxidized and
reduced CCO is dependent on and how it can be affected in vivo.
The redox state is dependent on both the availability of oxygen
in the cells and the supply of electrons entering the ETC. The
review by Cooper et al.31 gives an overview of the influencing
factors on the CCO redox state. In the purified isolated enzyme,
these include changes in the three substrates [protons (pH),
reduced cytochrome c, and oxygen tension], as well as a
range of terminal inhibitors (such as nitric oxide and cyanide)
and electrochemical potential. The complex interplay between
these factors in the mitochondrial ETC has been investigated
mathematically by Banaji.32 This informs on clinical in vivo
measurements. Possible factors that might increase oxCCO in
vivo include increase in oxygen tension, increased ATP turn-
over, decrease in proton electrochemical gradient, decrease in
pH, or decrease in supply of reducing equivalents (substrates,
i.e., NADH) to the ETC. These factors have been discussed
by Heekeren et al.33
The oxCCO concentration can readily be decreased in animal
models, either by large drops in oxygen tension or the addition
of inhibitors that act at the oxygen reduction site.16 There have,
though, been questions regarding how easy it is to increase the
oxCCO signal in vivo, but animal models have shown that there
is the capacity to increase the oxidation state at normoxia17,34 as
well as adult volunteer studies in hyperoxia and hypercap-
nia,13,35 and functional activation.12,33 We acknowledge that
there are some differences in the CCO response between the
preclinical and clinical work, in particular, when compared to
results from nonanesthetized human adults; it is not our inten-
tion in this review to discuss those physiological differences.
3 Methods of Cytochrome-C-Oxidase
Measurements
CCO is one of the most abundant enzymes in mammalian sys-
tems. However, its relatively low concentration compared to the
hemoglobin chromophores presents some challenges for NIRS
techniques. The absolute concentration of CCO in the human
brain is unknown, but optical methods have obtained values
of 5.5 and 4.5 μM in the adult rat.36,37 This should be considered
an upper limit for the human CCO concentration as rats have
a significantly higher cerebral metabolic rate of oxygen than
humans.31 The contribution of CCO to overall absorption in tis-
sue is considerably less than that of hemoglobin, because of its
lower concentration, despite a higher specific extinction spec-
trum in the NIR region. Although the detectable absolute con-
centrations may vary with species, age, and optical set up, it is
clear that the overall maximal signal from CCO should be 5% to
10% of that from hemoglobin. Therefore, light attenuation
changes due to CCO can easily be masked by the much larger
attenuation changes due to HbO2 and HHb; this can result in
cross talk. We define cross talk as a genuine change in one
chromophore concentration inducing a spurious measured con-
centration change in another. Specific instrumentation and algo-
rithms are necessary to be able to resolve these concentration
changes without cross talk and we discuss this later in Sec. 3.4.
The principles of NIRS [only continuous wave NIRS (CW
NIRS) is considered here] are based on calculating changes in
concentration from the changes in the measured light attenuation
in tissue. In order to do this, an algorithm and instrumentation
Fig. 4 The extinction spectra of the absorbing cytochromes in the electron transport chain in the visible
and NIR. The hemoglobin species extinction spectra are included for reference (450 to 740 nm
from Zijlstra et al.27 and 740 to 915 nm from Mark Cope,28 causing the discontinuity at 740 nm).
(a) Displayed between 400 and 1000 nm, note that the cytochrome b spectra are plotted on a secondary
axis and (b) zoomed into the NIR region of 700 to 900 nm. Oxidized and reduced spectra of cytochrome c
(oxCyt c and redCyt c, respectively) measured by Chris Cooper at the University of Essex in the porcine
heart. Oxidized and reduced spectra of CCO (oxCCO and redCCO) measured by John Moody at the
University of Plymouth in the bovine heart. Oxidized and reduced spectra of cytochrome b (oxCyt b and
redCyt b) measured by Mike Wilson at the University of Essex. All data taken from the UCL Biomedical
Optics Research Laboratory (BORL) website in Ref. 29.
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must be chosen, along with the selection of other variables, such
as the pathlength that the light has traveled, the absorption spec-
trum of the chromophore, and a set of measurement wavelengths.
It is important that the algorithm and the other variables do not
unknowingly induce artifacts. The factors that make up the algo-
rithm and its variables have been the subject of discussion for
many years. The choices to be made are:
• the algorithm
• the determination of the chromophore absorption spectra
• how the optical pathlength is estimated
• the number and choice of wavelengths.
Calculating and validating changes in hemoglobin in both of
its oxygenation states is simpler because its concentration in tis-
sue is high. It is also relatively simple to isolate the molecule to
produce an absorption spectra in vitro. The absorption spectra
have defined features in the NIR (see Fig. 5), such as a peak at
750 to 760 nm in HHb and the isobestic point at 800 nm. The
CCO difference absorption spectrum, once identified, has a
broad peak, which is significantly different to that of the hemo-
globin chromophores. However, the broad nature of the three
chromophore peaks throughout the NIR region confounds sim-
ple deconvolution via standard optical techniques, such as dual
wavelength or derivative spectroscopy. Therefore, to success-
fully separate the CCO signal from the larger hemoglobin
signals, careful selection of the algorithm, wavelengths, and
extinction spectra is required. One of the biggest problems
for the oxCCO signal is that there is no gold standard with
which to compare and validate the NIRS signal experimentally.
Although the same problem exists for NIRS detectable hemo-
globins, in this case, there are at least invasive measurements
that can be assumed to report on similar parameters (such as
tissue oxygen, blood volume, and arterial/venous oxygen satu-
ration). The lack of external comparators is a problem in assess-
ing which criteria produce the most physiologically accurate
oxCCO signal. Yet, there have been a range of in vitro and
in vivo controlled studies that inform on the success of the opti-
cal separation of the cellular oxCCO signal from changes in
the hemoglobin signals. Additionally, integrated mathematical
models of the biochemistry and physiology can aid the interpre-
tation of results.38–40
3.1 Algorithm
Various algorithms have been developed by different groups,
and these were assessed and described fully in 1995 by
Matcher et al.41 The algorithms can be reduced to those devel-
oped at Duke University (Duke), University College London
(UCL), Hokkaido University, Sapporo (Sapporo), and Keele
University (Keele).
The UCL algorithm is a generalized algorithm based on the
modified Beer–Lambert law and the concentrations are derived
using multilinear regression.42 The modified Beer–Lambert
law forms the mathematical basis of spectroscopic algorithms
that relate wavelength-dependent optical attenuation signals to
changes in chromophore concentrations. The generalized form
of this algorithm for n wavelengths (termed UCLn) is41
EQ-TARGET;temp:intralink-;e011;63;416
2
64
Δ½HbO2
Δ½HHb
Δ½oxCCO
3
75 ¼ 1
pathlength
2
666664
εHbO2ðλ1Þ εHHbðλ1Þ εoxCCOðλ1Þ
εHbO2ðλ2Þ εHHbðλ2Þ εoxCCOðλ2Þ
..
. ..
. ..
.
εHbO2ðλnÞ εHHbðλnÞ εoxCCOðλnÞ
3
777775
−1
×
2
666664
ΔAðλ1Þ
ΔAðλ2Þ
..
.
ΔAðλnÞ
3
777775
: (11)
The algorithm assumes that tissue scattering and pathlength
remain constant throughout the measurement period and is
therefore suitable for all geometries and optical systems. It
ignores, however, the multiple scattering effects including the
nonlinear relationship between absorption and attenuation;43
this is discussed further in the Sec. 3.2. A three-wavelength
version of this algorithm was also developed by researchers
at Keele using different extinction spectra.44
The algorithm developed in Sapporo is a four-wavelength
algorithm, which uses attenuation differences between three
measuring wavelengths and a fourth reference wavelength.45
The reference wavelength was selected in a region in which,
the authors claim, has zero attenuation from CCO. The algorithm
was developed specifically for the intact rat head through a ver-
tical plane from the roof of the mouth to the top of the skull. The
coefficients used (not shown here but presented in Refs. 41 and
46) contain optical instrumentation factors so are only specific to
one instrument. Their algorithm does not attempt to quantify the
concentration changes in hemoglobins and oxCCO, and thus
measurements are expressed in relative terms.46 The authors
assert their algorithm to be robust to changes in scattering and
optical pathlength changes during the measurement period.46
Fig. 5 Specific extinction coefficients measured by Mark Cope.28 The
ox-redCCO spectra are not the same as the difference between the
CCO spectra presented in Fig. 4. Data taken from the UCL BORL
website in Ref. 29.
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The Duke algorithm uses four wavelengths with specific
extinction spectra determined in vivo from the intact cat brain
to determine concentration changes.47 The algorithm is not
displayed here but can be found in Ref. 41, where it is also
discussed.
3.1.1 Chromophore Absorption Spectra
The difference between the oxidized and reduced form of CCO
can be determined in many different environments, such as the
isolated enzyme, in mitochondria, and in vivo. The first NIRS
measurement used difference spectra that were taken through
animal heads during anoxic challenges.1 These spectra showed
clear differences between oxidized and reduced CCO states.
Later, authors replaced blood with optically clear oxygen
carrying perfluorocarbon solutions in an attempt to produce
hemoglobin-free CCO spectra.18,21,48 In addition, later studies
were able to remove this contribution completely in rats,49,50
cats,51–53 and piglets.16
The use of perfluorocarbon perfused blood-free animals has
been a key to the development of algorithms to detect oxCCO.
In some cases, these spectra were themselves used to generate
the algorithms; in others, they were used to validate the use of in
vitro spectra. The latter was the case for the UCL algorithms.
Cope28 found that there is no appreciable difference between
the spectra measured in vivo and in vitro. Matcher et al.41 found
similar results when using the four-wavelength UCL algorithm,
which uses in vitro extinction spectra, and the three-wavelength
Keele algorithm, which uses in vitro spectra but with whole
blood, not purified hemoglobin, to resolve concentration
changes from the same attenuation data.
3.2 Optical Pathlength
The estimation of optical pathlength is one of the most notable
challenges for the calculation of changes in oxCCO, as it is
thought that erroneous changes resolved in oxCCO (i.e.,
cross talk) could be due to pathlength changes causing insuffi-
cient chromophore separation.16,23 As mentioned in Sec. 3.1, the
modified Beer–Lambert law does not account for tissue scatter-
ing and assumes that the reduced scattering coefficient (μ 0s) is
constant throughout a measurement period. The optical path-
length term is the only consideration of scattering in the
equation, so it must be estimated sufficiently to produce physio-
logically accurate representations of chromophore changes in
vivo.
The first attempts at optical pathlength estimation assumed a
constant pathlength, equal to the product of the distance between
the source and detector optodes and the differential pathlength
factor (DPF), an experimentally determined factor to account for
the increased pathlength of light due to all forms of scattering.42
The DPF can be determined using frequency-domain NIRS (FD
NIRS) or time-resolved NIRS (TR NIRS), which estimate the
optical pathlength.42,54,55 In addition, to monitor the changes
in pathlength in real time with CW NIRS, Matcher et al.56 at
UCL developed a method to resolve the pathlength using the
water absorption spectrum and the measured broadband attenu-
ation; features in the second differential of the water absorption
spectra around 740 and 820 nm can be combined with an
assumed tissue concentration of water to estimate pathlength.
In 1993, the modified Beer–Lambert law-based algorithm
was updated to account for the wavelength-dependency of
the DPF, which allowed for the decreasing scattering effects
at increasing wavelengths in tissue.57 DPF varies with wave-
length through another attenuation mechanism; high absorption
of light at a specific wavelength decreases the likelihood that
light at that wavelength will reach the detector.
A few experiments have been set up specifically to test
whether changes in pathlength are responsible for cross talk
in the oxCCO measurement; none of these studies found signifi-
cant changes in the pathlength during events where changes in
oxCCO were observed, such as hypoxemia58 or functional
activation.12,59 Skov and Greisen60 suggest that the wave-
length-dependent DPF is a solution to the cross talk problems;
they observed a linear relationship between HbT and oxCCO
during hypoxemia when using a constant DPF but not when
using wavelength-dependent DPF.
There are physiological factors that will affect tissue scatter-
ing. For example, glucose levels affect the refractive index of
extracellular fluid, which contributes to the reduced scattering
coefficient; therefore, changes in the glucose concentration
may affect the overall scattering of the tissue.61 Swelling of
the brain, or edema, is likely to change cerebral scattering
properties. There is therefore a need to understand the influence
of changing tissue scattering properties on the calculation of
chromophore concentrations or to measure scattering during
the measurement period, particularly in cases such as brain
injury.
3.3 Wavelength Selection
In theory, to extract information for three chromophores requires
measurements at three wavelengths. Yet this approach is prone
to noise and cross talk artifacts that may lead to inaccurate quan-
tification of changes in concentrations and misinterpretation of
data. When measurements at a larger number of wavelengths are
used in spectroscopic algorithms, any detrimental effects of
cross talk and noise are expected to diminish.
Due to the broad spectral peak in the oxidized-reduced CCO
spectra and its relatively low concentration in vivo, the choice of
selection of the specific wavelengths and number of wave-
lengths used for spectroscopy is a big factor. This is also relevant
for the hemoglobin chromophores. Matcher et al.41 performed
analysis to assess the separation of the oxCCO signal from
the hemoglobin signals with different number of wavelengths
(4, 6, and “n” or 112) in a range of data: rat head, piglet
head, adult forearm, and a simulated dataset. The results showed
that the higher number of wavelengths produced more accurate
simulations and improved the in vivo measurements. Despite
this, preclinical studies showed that limiting broadband mea-
surements from 780 to 900 nm improves the resolution of
oxCCO as exclusion of shorter wavelengths lessens the contri-
bution of HHb, which has a large peak at 760 nm.16 Figure 6
shows graphically the selection of wavelengths used in the clini-
cal papers mentioned in this review.
Broadband spectroscopy, offering a full range of measure-
ment wavelengths, can be difficult to incorporate into wireless
and multichannel systems. A recent study has used a genetic
algorithm method102 to assess the minimum number of wave-
lengths needed to resolve oxCCO accurately (compared to
the current gold standard of a broadband NIRS system across
780 to 900 nm at 1-nm wavelength resolution).62,103 The results
show that the optimal combination of wavelengths is a set that
almost evenly spans the spectral range (see Fig. 6). The error
against the gold standard reduces as the number of wavelengths
increases; increasing from 3 to 4, 5, and 8 wavelengths leads to a
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two-, three-, and sevenfold improvement in the reduction of
errors. The wavelengths selected need to be spread across
this range in order to resolve the shape of the ox-redCCO spectra
and disentangle it from the other chromophores; Arifler et al.62
found that the optimum eight wavelengths were 784, 800, 818,
835, 851, 868, 881, and 894 nm (displayed in Fig. 6).
3.4 Optical Instrumentation
Advances in optical methods have allowed further development
of the instrumentation, as well as the algorithm, which have con-
tributed to the increased robustness of the measured oxCCO
signal with NIRS. For a full review of NIRS instrumentation,
see Ref. 4.
Initially, NIRS instrumentation for the measurement of
oxCCO was performed using three or four narrowband lasers
at specific wavelengths between 740 and 910 nm22 (see Fig. 6,
for more examples) using a photomultiplier tube (PMT) for
detection. Commercial systems were developed to measure
oxCCO using four discrete wavelengths using lasers and either
photodiode detectors or PMTs (NIRO 300 and NIRO 500
respectively, Hamamatsu, Japan).82,86
In UCL, systems have increasingly been developed in-house
and focused on broadband spectroscopy in the aim of obtaining
a more robust oxCCO signal41 (see Sec. 3.4). These systems typ-
ically use a broadband white light source (i.e., a tungsten hal-
ogen bulb) with a spectrograph and charge-coupled device using
optical fibers to transmit light both to and from the tissue.10,96,104
The UCL broadband NIRS systems include (1) a broadband
instrument developed in the 1990s by Springett et al.;104
(2) a multidistance hybrid broadband and FD system developed
by Tachtsidis et al. in 2010 (called hybrid optical spectrometer
or pHOS);25,101 and (3) in 2014, two variations of that system
without the FD component developed by Bale et al.96 to be
used in neonates (called Cytochrome Research Instrument
and appLication or CYRIL),96 and Phan et al.105 with the capac-
ity to perform imaging. All UCL-developed systems are broad-
band instruments with the capacity to apply the UCLn algorithm
in real time and are explicitly mentioned in the reported stud-
ies below.
Miniaturization is a trend seen in all forms of technology and
NIRS is no exception. The trend toward making devices smaller,
more portable and cheaper has pushed broadband spectroscopy
toward miniature spectrometers,106 and discrete wavelength sys-
tems toward wireless NIRS.107 For wireless devices, in which
there is a need to eliminate heavy fiber optics, LEDs, and
laser diodes can be applied directly to the head with wireless
transmitters to send the data to a nearby computer. Versions of
both of these technologies are in development with the aim of
incorporating a measurement of oxCCO.108
In 2000, a combined CW and FD NIRS system was devel-
oped to use measurements of μ 0s and the absorption coefficient
(μa) to inform the calculation of absolute chromophore
concentrations.109 This was further developed by UCL to the
pHOS system that attempted to measure oxCCO using the
UCL hybrid algorithm.25,101 These hybrid devices use broad-
band CW systems and several lasers in the FD (7109 and 425
wavelengths) to achieve this. By resolving for both absorption
and scattering, it may be possible to measure absolute concen-
trations of the chromophores.
Fig. 6 Chart of wavelengths used in NIRS systems from all clinical publications mentioned in this review.
Systems are listed in chronological order from their first publication in this review and are separated
into three- and four-wavelength combinations and broadband spectra. The suggested wavelengths
determined by Arifler et al. are also shown in Ref. 62. Clinical papers using the wavelengths are
Duke 3λ,22,63,64 UCL 4λ,65 Duke 4λ,66–68 Keele 4λ,60,69–71 NIRO 1000,72–75 Keele 3λ,76,77 NIRO 500,78–85
NIRO 300,86–93 Critikon 2020,94 UCLn,7,41,58,95,96 Humboldt A,33,97 Humboldt B,98,99 and UCL
Hybrid.12,13,59,100,101
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It is important to ensure that the NIRS signals are sensitive to
the brain, but it is not possible to measure this experimentally.
Therefore, light propagation models have been used to estimate
the sensitivity of NIRS measurements to the brain in the
adult110,111 and neonate112–114 at different source–detector sepa-
rations. Due to the different geometries and tissue densities in
adults and neonates, there are differences in the propagation of
light.112 The cerebrospinal fluid (CSF) has a large positive
impact on the sensitivity of absorption change in the brain,110
whereas the skull thickness has a negative impact.111 The
thin skull and CSF layers in the neonate allow for more penetra-
tion of light into the cortex.112,113 Brigadoi et al.113 found that in
neonates, a source–detector separation of <2.14 mm has a brain
sensitivity of <5%, which means that signals from a typical set
up of ∼25-mm separation will have a significant cerebral con-
tribution; a source–detector separation of more than 8.4 mm will
achieve more than 5% brain sensitivity in adults. In addition,
computational modeling work from Fukui et al.112 suggest
that while the white matter sensitivity in adults is almost neg-
ligible, even for large (50 mm) source–detector separations, the
neonatal model shows high white matter sensitivity at as low as
10-mm separation. Furthermore, the CCO concentration in the
brain is likely to change with maturity. Rodent studies have
shown that there is an increase in the number of mitochondria
per cell, as well as an increase in the number of mitochondrial
proteins and respiratory enzymes per mitochondrion in the first
postnatal days.115 Additionally, there is a difference in energy
metabolism and functional activity in the rodent brain during
postnatal development compared with the adult, and so this
must be taken into consideration when monitoring CCO with
NIRS.
4 Analysis
4.1 Analysis of Broadband Cytochrome-C-Oxidase
Measurements
Here, we document clinical experiments that assess the oxCCO
signal for robustness and independence from other chromo-
phores (i.e., cross talk). We focus mainly on clinical papers
that use many wavelengths (broadband NIRS) and the wave-
length-dependent DPF methods, which are required to minimize
cross talk. We present a strong weight of evidence against cross
talk if a sufficient number of wavelengths are utilized.
The simplest way to assess cross talk is to compare the
oxCCO signals with the HbO2 and HHb, and this has been
done in many different experiments. In the assessment of the
low frequency oscillations during visual stimuli, there was a
phase shift between the hemodynamics and the oxCCO
signal.97 Additionally, the authors noted that the oxCCO record-
ings were “remarkably stable . . . compared to the changes in the
hemoglobins, making a simple cross talk rather improbable.”
Another functional activation study also showed differences
in the oxCCO directional changes despite normal hemodynamic
response functions.12 Furthermore, the same study confirmed
that there was no relationship between oxCCO and the measured
systemic changes. During blood pressure changes in orthostatic
hypotension patients, oxCCO dropped despite different HbT
directional responses.93 During spontaneous desaturation events
in infants with hypoxic-ischemic encephalopathy (HIE), differ-
ent directional changes were seen in oxCCO despite consistent
decreases in HbO2 and increases in HHb.
96 As discussed in
Sec. 3.2, no study, where oxCCO and pathlength have been
measured simultaneously, has a correlation been found between
their changes.
Uludag et al.98 found from simulations that incorrect estima-
tion of the wavelength dependency of partial pathlength can
contribute to cross talk in chromophores with low concentration.
However, when this was investigated experimentally by studies
in healthy adult volunteers using the Humboldt B broadband
NIRS system, they found that the majority of oxCCO changes
could not be explained by this effect.24
Wolf et al.94 investigated the changes in oxCCO in 22 pre-
term infants during slow oxygen saturation (SpO2) changes
caused by inspired O2 changes.
94 Changes in the concentrations
of HbO2, HHb, and HbT, induced by small and slow O2
changes, were inversely correlated to the measured changes
in the oxidation state of oxCCO with a four-wavelength
Critikon 2020.
The most compelling evidence of a unique metabolic signal
comes from human studies in which simultaneously measured
changes in metabolism have been made using other modalities.
Increases in oxCCO during hyperoxia correspond with
decreases in microdialysis measures of lactate/pyruvate ratio,
which is a marker of anaerobic metabolism.7 Tisdall et al.116
saw a linear relationship between oxCCO and estimated oxygen
delivery [measured via pulse oximetry and transcranial Doppler
(TCD) ultrasound] during hypoxemia. This relationship was not
seen between HbD and oxygen delivery.
Residual analysis enables an observation of the goodness of
fit of the chromophore spectra to the measured attenuation. To
see if the CCO difference spectrum is necessary to explain the
measured attenuation, two- and three-chromophore fits can be
performed with and without CCO. Heekeren et al.33 found
that using the three-chromophore fit explains in vivo data better
than the two-component fit.33 The residuals for two-component
fit have the same shape as oxCCO, which suggests that a
chromophore with a similar shape to oxCCO is needed to
fully explain the spectra. Above 760 nm, the three-component
fit residuals were random. This result was also found in other
broadband adult studies12,58 and a neonatal study96—an example
of this process is shown in Fig. 7.
5 Neonatal Studies
In this section, we review NIRS measures of oxCCO in neonates
during spontaneous changes in systemic physiology (e.g., peri-
ods of hypoxia, increases in blood pressure, and so on), during
surgery, with neonatal drug administration, and during func-
tional activation.
5.1 Hypoxia and Other Spontaneous Systemic
Changes
In 1985, Jöbsis’s group published the first NIRS study on new-
born infants.22 They observed a decrease in oxCCO during
spontaneous oxygen desaturations in three preterm infants
using the Duke three-wavelength system. Furthermore, the tim-
ing and magnitude of the oxCCO decrease depended on the
preceding oxygenation state, the depth and length of desatura-
tion event and presence of circulatory disorder. Another study
in which eight preterm infants were monitored with the
NIRO 1000 showed that small SpO2 changes did not alter
oxCCO.117 To add to the heterogeneity of the oxCCO response,
Wickramasinghe et al.118 saw an inconsistent (increases and
decreases) and insignificant change in oxCCO in seven infants
during the reduction of inspired oxygen fraction (FiO2; SpO2
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change ∼10%) using a three-wavelength Keele system.118 A
study of infants during repetitive apneas found a consistent
trend of reduced oxCCO during the breathing cycle.80 More
recently, a UCL broadband NIRS study (with CYRIL) of
over 200 oxygen desaturation events in six term infants with
HIE saw changes in the concentration of oxCCO in both direc-
tions but with a decrease in oxCCO on average.96 The hetero-
genic response to these hypoxias may be a reflection of the level
of brain injury, prematurity, previous oxygenation levels or in-
fluence of systemic pathophysiology. This heterogeneity is not
seen in adult broadband NIRS studies of controlled hypoxias12
(see Sec. 6.1) so is specific to the neonatal brain. Animal work
during anoxic swings in piglets has shown that as the oxygen
delivery rate is reduced, there is a linear decrease in HbO2
but a biphasic elbow in oxCCO reduction.104 A reduction in
oxCCO may be a signal of impending damage, and this has
also been previously suggested by Cooper et al.31 The hetero-
geneity of the oxCCO response to hypoxia has also been seen in
a piglet study of increasingly severe episodes of hypoxia.11 At
lower severities of hypoxia (8 and 12% FiO2), there were small
increases in oxCCO, while at higher degrees of hypoxia (6%,
4%, and 0% FiO2), oxCCO decreased with severity; consistent
decreases in HbO2 and corresponding increase in HHb were
observed in all hypoxic episodes. In 1985, Brazy called for
an investigation into the degree of CCO reduction that causes
brain injury in order to protect those at risk of injury;22 30
years later, there is still no answer but there is renewed effort
to find it.96
Following from the hypoxia work, the effect of respiratory
changes, which cause a subsequent change in carbon dioxide
tension (PaCO2), on the cerebral metabolism was investigated
in neonates. The 1985 infant study from Brazy et al.22 saw
oxCCO increase during hyperventilation; this was the first
human study to suggest that oxCCO is not maximally oxidized
in vivo at normoxia and can be increased by hyperventilation.
The ability to increase oxCCO from normoxia is supported by
another investigation where an increase in oxCCO was observed
during an increase in PaCO2.
71 Edwards et al.117 suggest that the
strong relationship between PaCO2 and oxCCO is either due to
cerebral hemodynamic changes caused by vasodilation due to
Fig. 7 Example residual analysis of NIRS data from the neonatal study by Bale et al.96 (a) SpO2 sponta-
neous decrease showing two time points, before and during hypoxia, from which the change in attenu-
ation is calculated. (b) Concentration results from fitting change in attenuation spectra to two- (HHb and
HbO2) and three- (HHb, HbO2, and ox-redCCO) component models. (c) Attenuation measured and
attenuation fit back-calculated from two- and three-chromophore fits. (d) Residual differences between
real attenuation and back-calculated attenuations, and the difference between them; note the shape of
the difference between the residuals for the two- and three-chromophore fits is similar to the ox-redCCO
spectra (also plotted for comparison on a separate scale).
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CO2, or CO2 decreasing the pH in cells. However, not all studies
have seen this strong correlation; a study of PaCO2 changes in
24 ventilated preterm infants observed changes in cerebral blood
flow and volume (CBF and CBV, respectively), but not in
oxCCO (four-wavelength Keele NIRS system).71 Brazy64
reported the effects of crying on oxCCO and found different
responses when lung disease was present and at different
ages of infant.64 An insignificant small decrease was observed
in oxCCO during endotracheal suctioning of 15 preterm infants
in the presence of marked decrease in HbO2 and increase in
HHb, monitored with the NIRO 500.82
Another early NIRS experiment examined changes in
oxCCO during alterations in mean arterial blood pressure
(MABP).63 This study showed that increases in MABP were
accompanied by increases in HbT and HHb and a decrease
in oxCCO as measured by a three-wavelength Duke system.
Infants whose clinical condition did not improve over the
study duration showed larger changes in HbT and oxCCO.
This area has potential for further investigation, especially in
terms of cerebral autoregulatory effects on tissue metabolism.
The effects of changing intracranial pressure (ICP) was
investigated during lumbar puncture75 in six infants with post-
hemorrhagic ventricular dilation with the NIRO 1000; three
infants had an increase in ICP, which was accompanied by
an increase in oxCCO, the other three had no change in either
ICP nor oxCCO; this is the only study to link oxCCO to ICP. In
a 2004 study of 12 infants with intraventricular hemorrhage,
removal of CSF, which is expected to cause a reduction of
ICP, did not produce a change in oxCCO measured with the
NIRO 500.83
5.2 Surgery and Anesthesia
Concern for cerebral health during major surgery such as cardio-
pulmonary bypass (CPB) brought the introduction of NIRS to
the operating room. The first use of oxCCO monitoring during
neonatal surgery was to monitor cerebral metabolism through-
out cardiac surgery. In 1991, 15 children were monitored during
CPB at Duke with a four-wavelength system66 and a decrease of
oxCCO was observed at onset of bypass with hypothermia and
reduced further when rewarming began. In 1995, 63 infants
were monitored during CPB and hypothermia, and interestingly,
oxCCO decreases were observed despite HbO2 increases mea-
sured by the NIRO 500.85 Recovery of oxCCO was delayed
despite HbO2 recovery to above baseline levels. Larger and
more rapid decreases were seen in oxCCO in older
(>14 days) infants and those infants had worse recovery. The
divergence in intravascular and mitochondrial oxygenation sug-
gests abnormal response, which the authors suggested could be
due to hypothermic temperature, effects of pH on the ETC, a
disturbance in oxygen delivery to the mitochondria, disturbed
perfusion, or decreased HbO2 dissociation. The delay in recov-
ery suggests mitochondrial dysfunction. Changes in hemo-
dynamics and oxCCO measured by a four-wavelength Keele
system were seen in 5 out of 14 children, who were hypoxemic
during CPB for congenital heart disease.60 Some recent studies
with the NIRO 300 during repair of coarctation of aorta (without
CPB)87 and cardiac surgery119 showed no significant change in
oxCCO throughout either procedure.
Other strains during surgery such as the use of therapeutic
hypothermia and anesthesia will have effects on cerebral
metabolism; such effects are interesting and important to under-
stand if NIRS monitoring of metabolism is to become clinically
relevant. However, as Du Plessis et al.85 note, it is difficult to
disentangle the effects of hypothermia on oxCCO from the path-
ology or the stress of surgery.
5.3 Effects of Drugs on the Neonatal Brain
The effects of the anesthetic, propofol, during CPB in children
(n ¼ 11) and CPB controls without propofol administration
(n ¼ 13) were studied in 2000.81 A decrease in oxCCO was
observed during CPB and a lower decrease was seen in those
with propofol.
The oxCCO response to other neonatal drugs, such as amino-
phylline, has been monitored. A NIRO 1000 was used to assess
aminophylline delivery to 13 preterm infants in order to wean
them off ventilators.74 A decrease in oxCCO was seen after ad-
ministration, which the authors suggest could be mediated by
reduction in perfusion of CO2. A later similar study, using
a NIRO 300 on the effects of aminophylline and caffeine for
treatment of apneas in preterm infants,89 found that neither
drug made a significant change to oxCCO.
Measures of oxCCO have been used to identify cerebral met-
abolic changes caused by indomethacin for the treatment of pat-
ent ductus arteriosus. Despite using different NIRS systems,
three separate studies recorded decreases in oxCCO, HbO2,
CBV, and CBF with increases in HHb when indomethacin
was administered.70,73,77 This result, combined with other evi-
dence from changes in CBF, has provided evidence against
the use of the drug due to its reduction in CBF and cerebral oxy-
gen consumption, in favor of other drugs, such as ibuprofen,
which do not have such a cerebral metabolic effect.120
5.4 Neonatal Brain Injury
In 1997, a review by Cooper and Springett23 highlighted the
potential for NIRS-measured oxCCO to monitor the progression
of neonatal HI brain injury. The management strategy of HIE
could be improved with additional information regarding the
cerebral metabolic state as the development of the injury pro-
gresses over time and can lead to a secondary energy failure
(SEF). There have been a handful of clinical studies of HIE with
oxCCO which have promising results. A study of 11 infants
with HIE showed that increases of SpO2 and PaCO2 increased
oxCCO (measured with the UCL4 algorithm), which is a normal
response and does not suggest pathophysiology.121 van Bel
et al.69 saw a CBVand oxCCO (using the Keele four-wavelength
algorithm) decrease in the first 12 h after birth in severe HIE, but
stable changes in mild HIE and controls; this could suggest the
delayed neuronal cell death as predicted by the animal models.
They also saw a positive relationship between PaCO2 and
oxCCO in all HIE infants.
Recently, the relationship between the UCLn NIRS-mea-
sured oxCCO and oxygen delivery (HbD) was investigated in
six HIE infants and found that an increased affinity between cer-
ebral metabolism and oxygenation indicated brain injury.96
Analysis of the rewarming data after therapeutic hypothermia
from this cohort provides more evidence that the relationship
between the multimodal signals is indicative of brain
injury.122 Further analysis of this data with a multivariate stat-
istical technique showed that a strong relationship between
oxCCO and the systemic physiology indicated more severe
brain injury (as measured by 31P MRS).123 This suggests that
the importance of the oxCCO measurement may not lie in
the signal itself, but in its relationship with oxygenation or
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systemic physiology, which can inform on the delicate equilib-
rium in pathology. However, most of this study occurred during
therapeutic hypothermia, now a routine treatment for HIE, so it
is difficult to compare with other earlier studies.
Furthermore, therapeutic hypothermia may make it difficult
to observe SEF and cause unusual metabolic responses, as men-
tioned before.85 As previously discussed, there need to be more
studies of the oxCCO response during cooling.
Recent animal studies of HIE have shown promising results.
The UCL group demonstrated a relationship between broadband
NIRS-measured oxCCO recovery fraction and HIE outcome in
a piglet model.10
The oxCCO signal has recently been observed during neo-
natal stroke in a term infant for the first time.124 Repeated tran-
sient decreases in cerebral HbT, HbD, and oxCCO were noted
on both cerebral hemispheres without significant changes in the
monitored systemic physiology. A clear asymmetry was noted
in the degree of change between the two sides of the brain.
Cerebral oxygenation (measured with HbD) and oxCCO were
only highly coupled on the injured side of the brain.
5.5 Functional Activation
There has been a huge wealth of work in fNIRS using HbO2 and
HHb as indicators of the hemodynamic response to neuronal
activity since it was first presented in 1993.125 We have an
opportunity with the oxCCO signal to inform directly on cer-
ebral metabolism during neurovascular coupling; there is no
other noninvasive, in vivo modality that can assess oxygen con-
sumption during functional tasks. Concerns have been raised
regarding the likelihood of measuring false positives or nega-
tives in the hemodynamic response using fNIRS from hemo-
dynamic signals that do not originate from neurovascular
coupling.14 Given that the oxCCO signal is more brain specific
than the hemodynamic signals, it could prove to be a very valu-
able addition to the fNIRS toolbox.12,13
There has only been one functional activation study involv-
ing infants and oxCCO and this used the NIRO 300. Nineteen
newborns were given auditory stimulus and no significant
oxCCO change was observed despite a normal hemodynamic
response.86 The expected response of oxCCO during functional
activation is unknown, although an increase is often seen
in adult studies of functional activation (see Sec. 6.2).
Differences between the mature and neonatal brain are sup-
ported by the NIRS study during cardiac surgery by Du
Plessis et al.,85 where different oxCCO responses were seen
at different ages. This could either reflect greater mitochondrial
hypoxic tolerance in younger infants or differences in the con-
centration of CCO at different ages.85
6 Adult Studies
In order to characterize measured changes in the oxCCO signal,
an increasing number of studies on adults have been performed
over the past 10 years. These studies fall into three categories:
volunteer studies with controlled inspired gas challenges to inves-
tigate the oxCCO response to systemic physiology, functional
activation studies on healthy volunteers, and clinical studies.
6.1 Volunteer Studies: Systemic Challenges
The first NIRS studies on adult volunteers were performed in the
early 1990s at Duke University. Hypoxic challenges were used to
assess the changes in oxCCO in the adult brain at normocapnia67
and hyper- and hypocapnia68 with four-wavelength Duke NIRS
systems. This work demonstrated a reduction of oxCCO during
hypoxia at all levels of PaCO2.
More recently, the UCL group has performed hypoxemia stud-
ies (SpO2 to 80%) during normocapnia in healthy volunteers
using the UCLn algorithm to estimate oxCCO.116,126 The hypoth-
esis was that in nonanesthetized humans, a significant decrease in
oxygen saturation should reduce oxCCO; this was confirmed in
the study. There was a linear correlation between oxygen delivery
[estimated from the measurement of the velocity of the middle
cerebral artery (Vmca), an indicator of changes in CBF as moni-
tored with TCD ultrasound] and oxCCO. A temporal delay
between the HbD drop and oxCCO of ∼5 s was also observed.
A later study using the pHOS and the UCLn algorithm confirmed
the decrease in oxCCO during hypoxia.13
Conversely, in hyperoxia, the oxCCO signal has been found
to increase.13,35 Tachtsidis et al.35 found that the oxCCO signal
as measured with the UCLn algorithm was correlated with TOI
(measured with the NIRO 300), as well as Vmca. Later, Kolyva
et al.13 repeated this study using the pHOS and also showed that
the magnitude of the oxCCO decrease during hypoxia was de-
pendent on the distance between the source and the detector.
The oxCCO response to changes in PaCO2 was investigated
first in 2009.35 During hypercapnia, Tachtsidis et al.35 increased
inspired CO2 and saw a significant increase in oxCCO (esti-
mated with the UCLn algorithm) and Vmca from baseline.
There was no correlation between oxCCO and Vmca, but
there were correlations with oxCCO and TOI (as measured
with the NIRO 300). More recently, Kolyva et al.13 confirmed
the increase in oxCCO during hypercapnia when monitored
with the UCL pHOS system. They also performed hypocapnia
and saw a decrease in oxCCO. Increased CO2 in the blood has
a vasodilatory effect, which can increase CBF, but it also
decreases the pH, which can reduce oxCCO. The authors
suggested that the increases in blood flow from hypercapnia
outweigh the potential damage to the respiratory chain from
acidosis. In these studies, the oxCCO signal had a different
trend to changes in HbT but showed a similar trend to TOI.
A hyperventilation experiment from a different group also
showed minor decreases in oxCCO with the NIRO 500.78
As well as answering physiological questions, the study by
Kolyva et al.13 was also designed to address scattering issues and
brain-specificity questions using the UCL pHOS system. The
magnitude of the oxCCO response increased with detector
distance, which was not true for the hemoglobin signals.
This oxCCO depth dependence shows that the signal is more
brain specific, which is due to the higher CCO concentration
in the brain, so the signal is less prone to extracerebral contami-
nation thanHbO2 and HHb. Neither this study
13 nor the previous
one116 saw any changes in pathlength during any of these
physiological challenges.
6.2 Volunteer Studies: Functional Activation
Functional activation in adults has been studied with fNIRS
since 1993 (see Sec. 5.5). Visual stimulation of the occipital cor-
tex provides a robust stimulation method. There have been a few
studies in this area to evaluate transient changes in the cellular
energy metabolism that occur during changes in neuronal activ-
ity. Heekeren et al.33 saw an oxCCO increase during functional
activation with a broadband NIRS (Humboldt A system); they
speculate that the cause of the increased oxCCO is not due to
increase in oxygen, as it would imply that the tissue is in a low
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PaO2 state normally, but due to decreases in proton electro-
chemical gradient increasing the rate of electron flow.33 This
phenomenon was also seen by the same group in later papers
with the Humboldt B broadband system.24,99 Fourier analysis
of the frequencies showed that oxCCO and HHb signals have
the same frequency as the stimulation, whereas HbO2 has
other peaks, which can be due to other factors.99
Significant heterogeneous oxCCO responses were seen in an
anagram-solving working memory study using the UCL pHOS
system.12,100 No group significant change in oxCCO was seen
during the anagram-solving task, but there were significant
increases and decreases seen in different subjects. In some sub-
jects, a significant decrease in oxCCO was seen in the presence
of a typical hemodynamic response (increase in HbO2 and
decrease in HHb).12,127 It is hard to predict or model the effect
of functional activation on oxCCO; the authors suggested that
the NADH oxidation and proton motive force can affect oxCCO
without affecting hemodynamics, which may provide an explan-
ation as to the heterogeneity of the oxCCO response despite a
consistent homogenous hemodynamic reaction. This would sup-
port the theory of Heereken et al.,33 which suggests a decrease in
supply of reducing equivalents (substrates, i.e., NADH) to the
ETC that might alter oxCCO without affecting the hemoglobins.
Different depths give different oxCCO responses, which
could be explained by spatial distribution of CCO, which is
more highly concentrated in the brain than in the extracerebral
tissue.12 A recent working-memory study with CYRIL at
multiple source–detector distances showed that the increase in
oxCCO observed in the longer channels was not present in
the short separation channels, despite a typical hemodynamic
response in all channels.128 The addition of the measurement
of the brain-specific oxCCO signal in fNIRS studies could
help identify false positives and negatives and solve the problem
of surface contamination.
6.3 Clinical Studies
Monitoring cerebral dysfunction in a clinical setting is important
both in cases where the brain is at risk of injury (e.g., cardiac
surgery) or where brain injury has already occurred [e.g., trau-
matic brain injury (TBI)]. There have been an increasing number
of clinical NIRS studies in adults for pathologies, such as
obstructive sleep apnea (OSA), cardiac surgery and hypoten-
sion, as well as brain injury itself.
The first investigation of cerebral oxCCO with NIRS during
surgery occurred in 1995 due to concerns regarding cerebral
stress of cardiac surgery causing postoperative neuropsycho-
logical damage. A NIRO 500 study of 41 patients undergoing
cardiac surgery with CPB found that patients who suffered from
neurological defects after surgery had lower minimum oxCCO
values during surgery compared to those without defects.129 The
oxCCO and venous saturation were inversely correlated during
CPB suggesting that an increase in oxygen saturation may not
be representative of an increase in tissue oxygenation. Kakihana
et al.130 using the Sapporo algorithm and instrument saw that
their measurement of oxCCO was a good predictor of postop-
erative cerebral outcome in a group of 66 patients who under-
went thoracic aortic surgery; the recovery fraction of broadband
NIRS-measured oxCCO following the surgery was predictive of
neurological outcome.
Further, in cardiac surgery investigators recorded changes
in oxCCO with the NIRO 300 during implantation of sub-
pectoral implantable cardioverter defibrillators under general
anesthesia.91 A random change in both directions was seen in
oxCCO (measured with the NIRO 300) during implantable car-
dioverter defibrillator testing, despite consistent decrease in
HbO2 and increase in HHb. This suggests that the availability
of oxygen at mitochondrial level was not consistently affected
by a short term lack of oxygen delivery and that mitochondrial
function may be able to identify cerebral abnormalities in this
group of patients that hemodynamic changes do not reveal.
A very early study also came to this conclusion,131 in patients
who were candidates for carotid endarterectomy, carotid artery
compression tests were performed and a reduction of oxCCO
was seen in some, but not all, patients. The authors suggest
that the presence of a decrease in oxCCO is indicative of
a more severe impairment of brain function.
A case study of an adult woman with a long-term neurologi-
cal disorder examined the oxCCO response to seizures with
the NIRO 500.79 Prior to seizure activity, a gradual increase
in HbO2 and HbT was observed with a simultaneous reduction
in oxCCO. Throughout the seizure there was an increase in
oxCCO, and HHb; seizures cause increased metabolic demand
and the increase in oxCCO corroborates this.
To investigate the response to hyperoxia in the brain injury,
eight patients with TBI undertook a hyperoxia challenge (60%
and 100% FiO2).
7 The concentration of oxCCO measured with
the UCLn algorithm increased during hyperoxia and correlated
with brain tissue oxygen tension as measured by microdialysis;7
there was a negative correlation between oxCCO and lactate/
pyruvate ratio which shows that the oxCCO NIRS changes
are related to cellular metabolism. Another investigation of
six patients with TBI showed a mean increase in oxCCO during
hypercapnia, but not in all individuals (four increase, two
decrease) despite increases in Vmca—this could be due to
heterogeneity of TBI.132 This study did not find an association
between oxCCO and the lactate/pyruvate ratio—the authors
suggest that this may be due to more complex changes induced
by CO2, such as pH, nitric oxide (NO) and cerebral metabolic
rate of oxygen (CMRO2) changes.
132
Bed tilts were performed in patients with primary autonomic
failure to assess cerebral oxCCO during hypotension measured
with the NIRO 300.93 There was a range of NIRS-measured
oxCCO responses during large decrease in HbD and HbT. In
patients where a significant decrease in oxCCO was observed,
there was a threshold in HbD and HbT reduction before it
occurred. A similar threshold has been seen in piglet studies of
anoxia,104 and may indicate the point at which damage to the
cells due to hypoxia and/or ischemia occurs.
Another population at risk of hypoxic injury is OSA patients
and these have been studied with the NIRO 300. The first study
looked at OSA patients during daytime naps with NIRS mon-
itoring, polysomnography, and laser Doppler.90 Correlations
were seen during spontaneous hypoxias between changes in
oxCCO and changes in TOI, CBF, SpO2, and MABP, there
was a weak negative correlation between oxCCO and end-
tidal CO2. The oxCCO signal was in phase with TOI but
not HbO2 or HHb. These results suggest that OSA hypoxias
cause anaerobic metabolism or CO2 changes to reduce CCO.
In another study of 62 sleep apnea patients, six had deep apneas
(TOI drop of >10%) and oxCCO dropped for each apnea.133
7 Discussion
NIRS-measured oxCCO has been studied in many clinical
environments. For neonates, this has included term and preterm
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infants, infants studied on neonatal intensive care units, and dur-
ing cardiac surgery. The results from the neonatal cohort are not
consistent, but that is largely due to the heterogeneity of the pop-
ulations studied and differences between the protocols. An
excellent example of the application of oxCCO in neonates is
the indomethacin work, which has shown that the oxCCO signal
can provide clinically important information.70,73,77 The most
recent work on neonatal HIE has shown that the relationship
between cerebral oxCCO and oxygenation is indicative of the
level of brain injury, as measured by a 31P MRS biomarker
of outcome,96 so oxCCO has potential clinical importance as
a bedside marker of cerebral well-being.
The literature on adults also covers a wide range of clinical
environments. The large study by Kakihana et al.130 is an excel-
lent example of the potential of oxCCO to be a clinical tool that
is predictive of neurological outcome after surgery. Further,
there is a great potential for the oxCCO measurement to be
used in fNIRS studies for a deeper understanding of oxygen
metabolism during neurovascular coupling and for its brain
specificity.12
The work on adults also covers a portfolio of volunteer stud-
ies, which have been used to deepen our knowledge of the
oxCCO signal in humans. The behavior of the oxidation state
of CCO is not fully understood as there is no gold standard
for the measurement in vivo. However, from the summary of
the results found in this review, we are able to summarize
the changes in its behavior from challenges performed on
healthy adult volunteers. We are limited to the adult brain as
it is not possible to obtain such controlled data on neonates.
Quantification of a normal oxCCO response in a healthy
brain will allow the identification of abnormal, and perhaps
pathophysiological, cerebral responses. The generalized trends
of the three NIRS chromophores in response to systemic
changes are summarized in Fig. 8.
Interpretation of a change in the oxidation state of CCO is
complex because it represents a change in equilibrium, which
may reflect fluctuations in any of several factors and the balance
between them including O2 supply, glucose or other substrate
supply, pH, temperature, and other ETC rates. Understanding
the CCO signal is sometimes challenging as there are many dif-
ferent factors that can cause increased oxidation or reduction of
the enzyme. This complexity can be dealt with by using com-
puter modeling of the physiology.81
The UCL group has developed a mathematical model of
the physiology of brain metabolism and circulation to aid the
interpretation of the measurable cerebral signals.38–40,134 The
first version of the model was an elaborate representation of
the adult brain134 and was extended to simulate changes in
the NIRS variables, in particular, changes in oxCCO.38 The
model has been used with NIRS-based adult studies,38 and
after modification for the piglet brain,39 has been used in con-
trolled preclinical studies of HIE.40
8 Future Directions
Measuring a real-time, bedside marker of brain tissue metabolism
is an active area of NIRS research. Many biomedical optics
groups are measuring cerebral CMRO2 with combined NIRS
and diffuse correlation spectroscopy.135–138 Others are combining
MRI and NIRS to measure CMRO2,
139 confirming the need for a
noninvasive measurement of tissue metabolism. We see NIRS-
measured oxCCO to be an alternative and/or complimentary
measurement to these other monitors of cerebral metabolism.
NIR imaging or diffuse optical tomography is under continu-
ous development.4 Recent work by Okada and Delpy110 demon-
strates the first oxCCO images acquired using a multichannel
broadband spectroscopy system during activation of the visual
cortex (Fig. 9). This work has demonstrated differences between
the localization of changes in oxCCO and the hemodynamic
signals (HbO2 and HHb). This difference could be due to
the oxCCO signal originating directly from the brain tissue,
while the hemoglobin signals result from changes in the sur-
rounding vasculature. Topographical images with oxCCO in
addition to HbO2 and HHb will allow investigation of regional
changes in cerebral oxygenation and oxygen consumption in the
healthy and injured brain.
The most challenging but exciting foreseeable development
for CCOwould be an absolute measurement. To resolve changes
in the oxidized concentration with respect to the reduced con-
centration of CCO would be revolutionary, as it would allow
easier comparison between patients or volunteers, and give
a better understanding of the state of tissue metabolism. The
UCL group is working toward methods to do this, with both
new hardware and algorithms. The group has recently developed
a multiwavelength TR spectrometer to quantify absolute
changes in absorption and scattering with a view to measuring
absolute CCO redox changes.140,141
In terms of the future of the instrumentation, we believe that
the capacity to measure changes in light attenuation using many
wavelengths is a key in separating the contribution of CCO from
the total attenuation spectra. While our recent theoretical work
suggests that measurements at a specific combination of eight
wavelengths (between 780 and 900 nm) can accurately resolve
oxCCO changes to 2% difference when compared to a broad-
band (121 wavelengths) measurement,62 we have yet to develop
and test an instrument that implements this solution. Instruments
based on broadband spectrometers with the capacity to measure
the changes in light attenuation at more than 100 wavelengths
have been extremely successful in separating the CCO signal
from the hemoglobins and are considered a key component
to an optimal CCO instrument. Broadband spectrometer
Fig. 8 Physiological stimuli and predicted NIRS-measured hemoglobin oxygenation and oxCCO
changes based on findings from this review for the healthy adult brain.
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instrumentation has advanced significantly the last 30 years and
we now have systems with enhanced light throughput and pho-
ton sensitivity in the NIR, with reduced noise and improved
electronics for fast acquisition, so they are robust enough to
be used in a clinical setting.96 In addition, through advances
in laser instrumentation and the development of supercontinuum
fiber laser sources, we now have the capacity to perform time-
of-flight measurements of multiple wavelengths of our choice,
allowing us to resolve tissue light absorption and scattering
across the NIR spectra to quantify oxCCO.140–142 Ten years
from now, we see NIRS instruments and cerebral oximeters
enhanced with the added capacity to measure oxCCO through
the utilization of an increased number of wavelengths.
9 Conclusion
In this review, we described the rationale, methods and analysis
behind NIRS measures of oxCCO. We summarized the range of
human brain studies (in healthy volunteers and patients) from
those first performed by the Jöbsis group, as early as 1985,
to the present day. We found 103 papers published on cerebral
oxCCO NIRS measurements in humans, 65% of the studies are
on adults, and the remaining 35% on neonates. The need for a
low-cost, bedside and noninvasive monitor of cerebral oxygen
metabolism remains an important and relevant goal for both
clinical and functional brain studies. This unmet need has driven
continued advances to deliver NIRS instrumentation and meth-
odologies, which are optimized specifically for CCO measures.
With this comes renewed focus on defining the role of the CCO
NIRS measurements in a range of clinical scenarios and fulfill-
ing Jöbsis’s vision for this optically derived metabolic marker.
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